Pacritinib(SB1518)

Min.Order / FOB Price:Get Latest Price

50 Milligram	Negotiable

50 Milligram

Negotiable

Min.Order :50 Milligram
Purity: ＞98％
Payment Terms : T/T,Other

Keywords

937272-79-2 98% purity in stock

Quick Details

Appearance:Off-white solid
Application:Laboratory research
PackAge:As your request
ProductionCapacity:|Metric Ton|Day
Storage:RT
Transportation:By air

Superiority:

High purity

NMR、HPLC will be offered

Fast delivery

Custom synthesis is available

Details:

Pacritinib (puh-CRIT-i-nib) is an oral tyrosine kinase inhibitor (TKI) with activity against two important activating mutations: Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). The JAK family of enzymes is a central component in signal transduction pathways, which are critical to normal blood cell growth and development as well as inflammatory cytokine expression and immune responses. Activating mutations of JAK2 are implicated in certain blood-related cancers, including myeloproliferative neoplasms (MPNs), leukemia and certain solid tumors. FLT3 is a gene commonly found mutated in patients with acute myeloid leukemia (AML). Pacritinib has demonstrated encouraging results in Phase 1 and 2 studies for patients with myelofibrosis and may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors.

View All

Visit Store